Philippe Aftimos

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney et al. · New England Journal of Medicine · 2021 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

François‐Clément Bidard, Virginia Kaklamani, Patrick Neven et al. · Journal of Clinical Oncology · 2022 · 695 citations · Full text

Medicine, Oncology, Pharmacology +15

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji, Carla M.L. van Herpen, Cristina Saura et al. · The Lancet Oncology · 2019 · 565 citations · Full text

Medicine, Oncology, Pharmacology +17

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis

Yacine Barèche, David Venet, Michail Ignatiadis et al. · Annals of Oncology · 2018 · 370 citations · Full text

Medicine, Molecular Biology, Oncology +16

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Aditya Bardia, Sara M. Tolaney, Kevin Punie et al. · Annals of Oncology · 2021 · 299 citations · Full text

Medicine, Oncology, Pharmacology +16